Skip to main content
. 2007 Sep;78(9):977–979. doi: 10.1136/jnnp.2006.105940

Table 3 Clinical data for patients with Parkinson disease and glucocerebrosidase mutations.

Study ID Mutation Age at onset* (y) Disease duration (y) Family history of PD Sex Additional information
Patients
 H44 L444P 60 7 N F L‐dopa response (+), motor fluctuation (+)
 H46 R120W 62 4 N M L‐dopa response (+)
 H80 RecNciI 34 8 N F L‐dopa response (+), motor fluctuation (+)
 H86 L444P 29 13 N M L‐dopa response (+), motor fluctuation (+), STN‐DBS implantation (+)
 H213 L444P 57 19 Y M L‐dopa response (+), motor fluctuation (+), STN‐DBS implantation (+)
 H351 L444P 57 11 N F L‐dopa response (+), motor fluctuation (+), STN‐DBS implantation (+)
 H434 L444P 46 3 N F L‐dopa response (+), motor fluctuation (+)
 H507 L444P 64 12 N F L‐dopa response (+), motor fluctuation (+), dementia (+)
 H590 L444P 67 4 N F L‐dopa response (+)
 H707 L444P 55 5 N M L‐dopa response (+)
 H837 L444P 46 3 N M L‐dopa response (+)
 H867 L444P 64 2 N M L‐dopa response (+)
 H1279 L444P 30 8 N M L‐dopa response (+), motor fluctuation (+)
 H1405 RecNciI 49 4 N F L‐dopa response (+), depression (+)
 H1421 L444P 50 7 N F L‐dopa response (+), depression (+)
 H1500 L444P 40 7 N M L‐dopa response (+), motor fluctuation (+)
Controls
 C769 L444P 76 N F
 C806 L444P 73 N F
 C877 RecNciI 57 N F
 C972 RecNciI 43 N F

PD, Parkinson disease; STN‐DBS, subthalamic nucleus deep brain stimulation.

*Age at study inclusion for control individuals.